Michael Narachi - Net Worth and Insider Trading
Michael Narachi Net Worth
The estimated net worth of Michael Narachi is at least $103,156 dollars as of 2024-05-11. Michael Narachi is the Director of AMAG Pharmaceuticals Inc and owns about 7,500 shares of AMAG Pharmaceuticals Inc (AMAG) stock worth over $103,125. Michael Narachi is also the President and CEO of Orexigen Therapeutics Inc and owns about 5,803 shares of Orexigen Therapeutics Inc (OREXQ) stock worth over $31. Details can be seen in Michael Narachi's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Michael Narachi has not made any transactions after 2014-09-15 and currently still holds the listed stock(s).
Transaction Summary of Michael Narachi
Michael Narachi Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Michael Narachi owns 4 companies in total, including Ultragenyx Pharmaceutical Inc (RARE) , Orexigen Therapeutics Inc (OREXQ) , and Eiger BioPharmaceuticals Inc (EIGRQ) among others .
Click here to see the complete history of Michael Narachi’s form 4 insider trades.
Insider Ownership Summary of Michael Narachi
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RARE | Ultragenyx Pharmaceutical Inc | 2015-02-20 | director |
| OREXQ | Orexigen Therapeutics Inc | 2017-10-13 | director & CEO & President |
| EIGRQ | Eiger BioPharmaceuticals Inc | 2014-01-29 | director |
 | | 2013-05-23 | director |
Michael Narachi Latest Holdings Summary
Michael Narachi currently owns a total of 2 stocks. Among these stocks, Michael Narachi owns 7,500 shares of AMAG Pharmaceuticals Inc (AMAG) as of May 25, 2012, with a value of $103,125 and a weighting of 99.97%. Michael Narachi also owns 5,803 shares of Orexigen Therapeutics Inc (OREXQ) as of September 15, 2014, with a value of $31 and a weighting of 0.03%.
Latest Holdings of Michael Narachi
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| AMAG | AMAG Pharmaceuticals Inc | 2012-05-25 | 7,500 | 13.75 | 103,125 |
| OREXQ | Orexigen Therapeutics Inc | 2014-09-15 | 5,803 | 0.01 | 31 |
Holding Weightings of Michael Narachi
Michael Narachi Form 4 Trading Tracker
According to the SEC Form 4 filings, Michael Narachi has made a total of 0 transactions in AMAG Pharmaceuticals Inc (AMAG) over the past 5 years. The most-recent trade in AMAG Pharmaceuticals Inc is the acquisition of 7,500 shares on May 25, 2012, which cost Michael Narachi around $27,075.
According to the SEC Form 4 filings, Michael Narachi has made a total of 0 transactions in Orexigen Therapeutics Inc (OREXQ) over the past 5 years. The most-recent trade in Orexigen Therapeutics Inc is the acquisition of 5,000 shares on September 15, 2014, which cost Michael Narachi around $239,000.
Insider Trading History of Michael Narachi
- 1
Michael Narachi Trading Performance
GuruFocus tracks the stock performance after each of Michael Narachi's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael Narachi is 15.29%. GuruFocus also compares Michael Narachi's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael Narachi within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Michael Narachi's insider trading performs compared to the benchmark.
Performance of Michael Narachi
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -5.66 | | | | | |
| Relative Return to S&P 500(%) | -2.44 | | | | | |
Michael Narachi Ownership Network
Michael Narachi Owned Company Details
What does Ultragenyx Pharmaceutical Inc do?
Who are the key executives at Ultragenyx Pharmaceutical Inc?
Michael Narachi is the director of Ultragenyx Pharmaceutical Inc. Other key executives at Ultragenyx Pharmaceutical Inc include EVP and Chief Medical Officer Eric Crombez , CBO & Senior Vice President Thomas Richard Kassberg , and EVP and General Counsel Karah Herdman Parschauer .
Ultragenyx Pharmaceutical Inc (RARE) Insider Trades Summary
Over the past 18 months, Michael Narachi made no insider transaction in Ultragenyx Pharmaceutical Inc (RARE). Other recent insider transactions involving Ultragenyx Pharmaceutical Inc (RARE) include a net sale of 5,605 shares made by Theodore Alan Huizenga , a net sale of 127,435 shares made by Emil D Kakkis , and a net sale of 54,366 shares made by Thomas Richard Kassberg .
In summary, during the past 3 months, insiders sold 39,487 shares of Ultragenyx Pharmaceutical Inc (RARE) in total and bought 0 shares, with a net sale of 39,487 shares. During the past 18 months, 243,647 shares of Ultragenyx Pharmaceutical Inc (RARE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 243,647 shares.
Ultragenyx Pharmaceutical Inc (RARE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ultragenyx Pharmaceutical Inc Insider Transactions
Michael Narachi Mailing Address
Above is the net worth, insider trading, and ownership report for Michael Narachi. You might contact Michael Narachi via mailing address: C/o Orexigen Therapeutics, Inc., 3344 N Torrey Pines Ct, #200, La Jolla Ca 92037.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
